Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Executive Summary
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
You may also be interested in...
Lovenox Quest For Fresh Patent Continues; ANDAs May Face “Premarin” Problem
Aventis will continue to pursue a re-issuance of its low weight heparinLovenox patent despite a second rejection by the Patent & Trademark Office
Lovenox Quest For Fresh Patent Continues; ANDAs May Face “Premarin” Problem
Aventis will continue to pursue a re-issuance of its low weight heparinLovenox patent despite a second rejection by the Patent & Trademark Office
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition